WHO ICTRP trial
The exploratory, multicenter, open-label study to evaluate the effect of…
JPRN-jRCTs031200048 · Japan Primary Registries Network (JPRN) · Not Recruiting
Key facts
| Trial ID | JPRN-jRCTs031200048 |
|---|---|
| Public title | The exploratory, multicenter, open-label study to evaluate the effect of linaclotide on the Japanese version of Patient Assessment of Constipation of Quality of Life Scale (JPAC-QOL) in patients whose QOL scale is poor in spite of taking magnesium oxide with adult chronic constipation |
| Scientific title | The exploratory, multicenter, open-label study to evaluate the effect of linaclotide on the Japanese version of Patient Assessment of Constipation of Quality of Life Scale (JPAC-QOL) in patients whose QOL scale is poor in spite of taking magnesium oxide with adult chronic constipation |
| Primary sponsor | Yoshihara Tsutomu |
| Secondary sponsors | Astellas Pharma Inc. |
| Registry | Japan Primary Registries Network (JPRN) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Conditions | Adult patients with CC or IBS-C whose primary treatment of MgO was insufficiently effective CC, Chronic constipation, IBS-C, Irritable bowel syndrome with constipation;CC, Chronic constipation, IBS-C, Irritable bowel syndrome with… |
| Interventions | Patients take 0.5 mg of linaclotide once daily (Two tablets of Linzess tablets 0.25 mg, orally administered before meals) for 12 weeks.;Linaclotide, Linzess |
| Registration date | Sep 6, 2020 |
| Target size | 64 |
| Registry page | jrct.niph.go.jp |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: